Coumarin Derivative 3-Week Dosing Cycles to Limit Skin Rash
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dosing regimens for compound (I) or its salts, administered twice weekly at 4 mg per administration, often result in adverse skin reactions leading to unplanned dose interruptions and reductions, limiting their safe and long-term use in treating cell proliferative disorders like cancer.
Innovation Solution
A dosing regimen involving administration of compound (I) or its salts twice weekly for 3 weeks, followed by a 1-week pause, with the cycle repeated at least once, allowing for safe and prolonged use while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compound (I) or its salt is administered twice weekly at 4 mg per administration, then antitumor activity is improved, but skin rash and adverse events worsen leading to dose interruption
Solution Approach 1:
The patent applies periodic action by implementing a dosing regimen that cycles between administration periods (3 weeks) and interruption periods (1 week). This periodic pattern allows the drug to exert its antitumor effect during administration phases while providing recovery time during interruption phases, thereby reducing cumulative skin rash and other adverse events that occur with continuous dosing.
2Duration of action of stationary object
If compound (I) or its salt is administered continuously, then treatment duration is extended, but adverse events accumulate requiring dose reduction
Solution Approach 1:
The patent applies segmentation by dividing the continuous treatment into discrete cycles, each consisting of a 3-week administration phase followed by a 1-week interruption phase. This segmentation allows the treatment to be maintained over extended periods by periodically resetting the accumulation of adverse events, thereby enabling long-term treatment without continuous dose reduction.
Data Source
AI summary
The present invention provides a method for the treatment or prevention of a cell proliferative disorder, the method comprising:(a) administering a compound represented by formula (I):or a pharmaceutically acceptable salt thereof twice weekly for 3 weeks,(b) pausing administration of said compound or salt for the following 1 week, and(c) subsequently repeating steps (a) and (b) at least once.